7 Green Days In A Row: Everpure Stock Is Up 28%

SPYYTD+13.5%QQQYTD+22.3%
Analyze P →

Shares of Everpure (P) have closed higher in each of the last 7 sessions, a cumulative gain of 27.8%. That added about $10.2 billion to the company’s market value, which now stands at about $46.7 billion. The stock closed at $140.14 on Friday, October 2.

Image from Pixabay

 
The Streak Next To The S&P 500

Returns for P and the S&P 500 over the streak and the periods around it, all ending Friday, October 2 and including dividends:
 

Return Period P S&P 500
1 Day 4.5% 0.7%
7 Days (Current Streak) 27.8% 0.2%
1 Month (21 Trading Days) 51.6% 0.8%
3 Months (63 Trading Days) 80.3% 2.7%

How The Streak Compares With The Market

Over the same 7 trading days, the S&P 500 returned +0.2% including dividends, so the run is mostly Everpure’s own story rather than the market’s. 1 other S&P 500 stock is currently on winning streaks of 7 days or longer. Over the past three months the stock is up 80.3%, a window that includes the streak; over the other 56 sessions of that window it was up 41.1%.

Do The Fundamentals Support The Run?

On the fundamentals, revenue grew 27.2% over the last twelve months, against a median of 17.9% for S&P 500 Information Technology stocks; its operating margin is 5.3%, versus a median of 21.7%; and the stock trades at 184.2 times trailing earnings against a median of 37.2. The numbers make the run harder to justify: margins below the median and a multiple well above the median. At this price, the stock is asking a lot of the business.

A climb like this is worth respecting, and worth testing. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.

One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy

A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?

The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Follow the story; invest in the strategy.